Risk of major adverse cardiovascular events for concomitant use of clopidogrel and proton pump inhibitors in patients inheriting CYP2C19 loss-of-function alleles: meta-analysis
Conclusion Patients inheritingCYP2C19 loss-of-function alleles have significantly increased risk of major adverse cardiovascular events when taking clopidogrel and proton pump inhibitors concurrently.
Source: International Journal of Clinical Pharmacy - Category: Drugs & Pharmacology Source Type: research
More News: Cardiology | Cardiovascular | Clopidogrel | Coronary Heart Disease | Drugs & Pharmacology | Genetics | Heart | Heart Disease | Plavix | Proton Pump Inhibitors PPIs | Statistics | Stroke | Study